CareDx (CDNA) EPS Beats Sales Gain 14%

CareDx (NASDAQ:CDNA), a molecular diagnostics company specializing in transplant care solutions, released its results for the second quarter of fiscal 2025 on August 6, 2025. The big news from the release was a solid beat on non-GAAP earnings per share, reporting $0.10 against an expected loss, despite a very slight non-GAAP revenue shortfall versus expectations. Non-GAAP adjusted revenue was $90.5 million, up 14% from the prior year but just short of the $90.6 million non-GAAP consensus. Testing service volumes continued their streak of growth, reaching 49,500, and the company’s adjusted EBITDA swung positive year over year. Management narrowed its full-year 2025 revenue guidance to $367 million to $373 million but reaffirmed its adjusted EBITDA target of $29 million to $33 million for FY2025, underscoring progress in driving operational discipline even as margins faced pressure in the period. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. CareDx develops diagnostic tests, digital solutions, and associated products focused on improving outcomes for organ transplant patients. Its flagship offerings include AlloSure kidney, heart, and lung surveillance tests, which use molecular techniques to monitor for signs of organ rejection more effectively than conventional approaches.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool